All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 25th May 2017, the European Medicines Agency’s (EMAs) Committee for Orphan Medicinal Products (COMP) granted Orphan Drug Designation for GMI-1271, a novel E-selectin (E-sel) antagonist , for the treatment of patients with Acute Myeloid Leukemia (AML).1 This comes after GMI-1271 was granted an orphan drug designation for the treatment of Relapsed or Refractory (R/R) AML by the U.S. Food and Drug Administration (FDA) earlier this month.
GMI-1271 is a novel antagonist of E-sel, (a cell adhesion molecule that contributes to leukemic cell survival pathways) and acts by disrupting leukemia cell survival pathways thus enhancing chemotherapy response.2,3
GMI-1271 is currently being investigated in the phase 2 portion of the phase 1/2 study (NCT02306291), which is aiming to assess the safety, efficacy and pharmacokinetics of this agent in combination with standard chemotherapy in patients with R/R AML and also in AML patients 60 years of age and older with newly diagnosed disease. Results from this study will be presented during this year’s American Society of Clinical Oncology Annual Meeting, taking place in Chicago between 2nd–6th June and also at the European Hematology Association (EHA) congress taking place in Madrid between 22nd–26th June.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox